Quest Acquiring Celera for $671M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics and Celera today announced they have signed a definitive agreement for the purchase of Celera by Quest for $671 million, or $344 million net of cash and short-term investments.

Quest will pay $8 for each share of Celera. The deal includes $327 million in acquired cash and short-term investments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.